Teresa Bitetti is President of the Global Oncology Business Unit of Takeda Pharmaceutical Company Ltd. She joined the company in April 2019 and is responsible for oncology business activities around the world, overseeing a global portfolio consisting of therapies in hematological malignancies and lung cancer.
Prior to joining Takeda, Ms. Bitetti spent more than 20 years at Bristol-Myers Squibb (BMS), where she held several leadership roles, including Senior Vice President, Head of Worldwide Oncology Commercialization. During her tenure, she oversaw the launch of Opdivo in the U.S. market and significantly enhanced the long-term strategic direction of the immuno-oncology portfolio.
Before BMS, Ms. Bitetti held various roles of increasing responsibility at Mobil Oil Corporation, where she was part of the Capital Markets Group and responsible for the investment of Mobil's worldwide pension assets.
Ms. Bitetti holds an MBA in Finance from the Darden School of Business at the University of Virginia and a B.A. in Classical Civilization from Wellesley College.